LYFCX Fees and Costs — AlphaCentric Life Sciences and Healthcare Fund, Class C
Data updated: 2026-08-27
The net expense ratio is 2.41%: a 1.25% management fee, a 1.00% 12b-1 fee plus 0.82% other expenses, less a 0.67% fee waiver. There are no sales loads or redemption fees. In fiscal 2026 the fund paid $56K in broker commissions, 0.1533% of average net assets, and portfolio turnover was 107%.
LYFCX Fees and Expenses
Annual operating expenses and sales charges of LYFCX. Prospectus, as of July 28, 2026.
| Annual operating expenses | |
|---|---|
| Management fee | 1.25% |
| 12b-1 fee | 1.00% |
| Other expenses | 0.82% |
| Gross expense ratio | 3.08% |
| Fee waiver | −0.67% |
| Net expense ratio | 2.41% |
| Sales charges | |
|---|---|
| Max front load | 0.00% |
| Max deferred load | 0.00% |
| Redemption fee | 0.00% |
| Expense limitation in place (N-CEN) | Yes |
| Fees waived or reduced during the year | Yes |
| Waived fees subject to recoupment | Yes |
LYFCX Costs Over Time
On $10,000 invested in LYFCX, assuming 5% a year before costs, total costs come to $1,554 over 5 years, cutting the return by 2.69% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Fund expenses (net expense ratio 2.41%) | $253 | $777 | $1,325 |
| Trading costs (broker commissions) | $16 | $49 | $84 |
| Lost growth on money paid in costs | $0 | $41 | $145 |
| Total costs | $269 | $868 | $1,554 |
| Value after costs | $10,231 | $10,709 | $11,209 |
| Impact on return, per year | 2.69% | 2.69% | 2.69% |
LYFCX Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending March 31, 2026.
- Explicit cost rate (commissions ÷ average net assets): 0.1533%
- Total broker commissions: $56K
- Bought from dealers (principal trades, not a cost): —
- Portfolio turnover (prospectus): 107%
- Securities lending: none during the year
LYFCX Agency Brokers
Commissions paid.
| Broker | Amount | Share |
|---|---|---|
| Northern Trust Securities, Inc. | $56K | 100.00% |
AlphaCentric Life Sciences and Healthcare Fund Share Classes
Net expense ratio and maximum front-end load of each share class, cheapest first.
| Ticker | Class | Net expense ratio | Front load |
|---|---|---|---|
| LYFIX | Class I | 1.41% | none |
| LYFAX | Class A | 1.66% | 5.75% |
| LYFCX | Class C | 2.41% | none |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.